OTLK Stock Forecast & Price Target

Outlook Therapeutics Inc. has demonstrated a positive growth trajectory with the increasing uptake of its ophthalmic product, Lytenava, which saw unit sales more than doubling in the UK and Germany in the first quarter of 2026 compared to the previous quarter. The company is planning to expand its market presence by launching Lytenava in additional key EU markets such as France, Italy, and Spain in 2027, which could further enhance revenue growth prospects. While the company has experienced a narrowing of operating losses and anticipates rapid revenue growth following its recent commercial launch, the potential approval of ONS-5010 by the FDA is expected to provide significant upside to the stock, despite current financial challenges.

Outlook Therapeutics Inc has experienced a significant decline in R&D and G&A expenses, with R&D costs dropping 62.4% year-over-year to $3.6 million, and G&A expenses falling 27.9% to $8.6 million, both exceeding expectations but indicating potential challenges in funding ongoing development. The U.S. ranibizumab market's steep decline raises concerns about the demand for the company’s sole active product, ONS-5010, especially as sales remain insufficient to generate positive revenue. Furthermore, multiple risks, including the dependence on a single development program, uncertain clinical trial outcomes, competition from new therapies, and the need for additional financing to achieve profitability, contribute to a negative outlook for the company’s stock performance.